XyloCor raises $67.5M Series B, updates pivotal gene therapy trial plansnews2025-01-07T12:30:45+00:00January 7th, 2025|Endpoints News|
Exclusive: Avenzo picks up another ADC, this time with multi-partnered DualityBionews2025-01-07T12:00:59+00:00January 7th, 2025|Endpoints News|
Vertex signs in vivo gene editing delivery pact for sickle cell and thalassemia with Orna Therapeuticsnews2025-01-07T12:00:02+00:00January 7th, 2025|Endpoints News|
Ken Song’s Candid licenses a T cell engager from WuXi Bionews2025-01-07T11:50:30+00:00January 7th, 2025|Endpoints News|
Highlander Health acquires Target RWE to improve clinical trialsnews2025-01-07T11:00:39+00:00January 7th, 2025|Endpoints News|
Teoxane issues competing buyout bid for Revance and its Botox rivalnews2025-01-06T20:31:11+00:00January 6th, 2025|Endpoints News|
Regeneron buys London-based ocular biotechnews2025-01-02T18:46:53+00:00January 2nd, 2025|Endpoints News|
Roche circles back to China biotech with $80M deal for lung cancer ADCnews2025-01-02T11:39:42+00:00January 2nd, 2025|Endpoints News|
Deerfield to buy Singular Genomics, beating out rivalnews2024-12-23T17:56:16+00:00December 23rd, 2024|Endpoints News|
Jim Wilson’s GemmaBio raises $34M to commercialize gene therapies for rare diseasesnews2024-12-23T16:20:00+00:00December 23rd, 2024|Endpoints News|
